InsightfulDiscussion

#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

The Tim Ferriss Show2h 15m

Jake Becraft, CEO of Strand Therapeutics, discusses the future of genetic medicine with Tim Ferriss across two conversations spanning two months. The first covers brainstorming about messaging and policy reform around clinical trials, while the second reflects on how that messaging reached the President's office and shaped legislative priorities.

Summary

In this two-part conversation, Jake Becraft presents Strand Therapeutics' work on programmable genetic medicines, specifically RNA-based therapies that can be delivered to diseased cells throughout the body. Part one focuses on Strand's breakthrough results showing an abscopal response (immune system activation spreading from injected tumors to distant metastases) in cancer patients, and explores the regulatory and messaging challenges in biotech.

Becraft explains that genetic medicine has been trapped in the liver for 30 years due to delivery limitations. Strand is attempting to solve what he calls the "holy grail" of genetic medicine: intravenous administration to reach multiple organs. He describes how they inject RNA instructions into cancer cells, causing tumors to activate immune responses that spread throughout the body. He emphasizes the distinction between a "good drug" (that helps a patient) and a "good product" (that can be deployed at scale economically).

A critical theme is the contrast between discovery and deployment. While AI has accelerated protein design (through AlphaFold), the bottleneck has shifted from knowing what proteins to make toward delivering those proteins to the right cells. Becraft argues this requires three components: potency, specificity, and delivery—not just delivery alone.

The first conversation centers on messaging strategy. Ferriss introduces split-testing via PickFu to optimize headlines and messaging angles. They discover that framing problems with solution-oriented language ("this is bad, but here's how to fix it") resonates far better than problem-only framing. Becraft discusses his frustration with biotech conservatism and advocates for first-principles thinking similar to SpaceX's approach to rocketry.

A major focus is FDA regulatory reform. Becraft argues that current IND (Investigational New Drug) applications cost $25 million and take 18 months, pushing clinical trials to Australia and China. He proposes adopting Australia's CTN (Clinical Trial Notification) system, where companies notify regulators and work directly with hospital IRBs (Institutional Review Boards) rather than seeking FDA permission. This would distribute safety oversight across certified IRBs nationwide, reduce costs, accelerate trials, and enable more hospitals to run first-in-human studies.

Part two, recorded two months later, reveals remarkable progress. Becraft's Washington Post op-ed titled "The US Can't Afford to Offshore Clinical Trials to China" gained traction in biotech and policy circles. Congressional staff invited him to testify about biomedical competitiveness and threats from China. Within weeks, the President included FDA reform language in his legislative priorities to Congress—a remarkable two-month turnaround for policy change.

They discuss what messaging worked. The opportunity framing ("we can fix this") proved more compelling than alarm. They split-tested multiple headlines, discovering which drove engagement. Becraft reflects that making people "care" is prerequisite to learning; scientists naturally care about science, but policymakers need narrative hooks and clear solutions.

The conversation expands to broader themes about platform therapeutics. Becraft draws parallels to SpaceX (reusable rockets enabling multiple missions), Amazon (long-term patient capital despite short-term losses), and Apple (creating delivery infrastructure that enabled ecosystems). He argues biotech has become myopic, optimized for acquisition by Big Pharma rather than building transformational companies. The industry defaults to incremental innovation because the cost of failure is high, discouraging bold bets.

Becraft articulates Strand's vision as building multiple platform delivery systems for different body regions (tumors, T-cells, kidneys, brain) rather than one universal platform. Each platform represents years of R&D; the hope is that eventual personalized medicine becomes economically viable once delivery infrastructure scales.

They discuss capital formation challenges. SpaceX succeeded partly because Elon was already wealthy and willing to risk bankruptcy; Amazon succeeded through disciplining Wall Street to accept long-term losses. Becraft sees his role as CEO as finding global partners—both capital and intellectual—aligned with a 20-30 year mission rather than seeking near-term exits. He references Jeff Bezos's shareholder letters as models for communicating long-term vision in the public market.

The conversation touches on political constraints (mRNA's COVID politicization makes it a weaker analogy) and explores better historical examples like Genentech's insulin platform or Genzyme's recombinant protein approach. He notes how biotech has been "pulled" by Big Pharma acquisition incentives, causing the entire industry to optimize for acquirability rather than building generational companies.

Becraft emphasizes that true platform value comes from being payload-agnostic—once you solve delivery to tumors, you can deliver different therapeutic proteins repeatedly without revalidating the entire platform. This mirrors Moderna's 12 years of foundational mRNA work before the 62-day COVID vaccine development.

The piece concludes with reflection on hyper-personalization as medicine's future. Right now, economics don't support bespoke therapies. But as delivery infrastructure matures and scales (similar to how smartphones made Spotify possible), personalized genetic medicines become viable. The near-term mission is building that infrastructure through platform development and regulatory reform.

About this episode

<p><a href="https://x.com/DrSynbio" rel="noopener noreferrer" target="_blank">Jake Becraft</a> is the CEO and co-founder of <a href="https://www.strandtx.com/" rel="noopener noreferrer" target="_blank"><strong>Strand Therapeutics</strong></a>, a company building one of the most advanced programmable genetic medicine platforms in biotechnology. Under his leadership, Strand is redefining what RNA medicines can do by enabling cell-selective targeting and therapeutic payload delivery inside the body, unlocking a new class of precision genetic therapies.</p><p><strong>This episode is brought to you by:</strong></p><ul><li><a href="https://helixsleep.com/tim" rel="noopener noreferrer" target="_blank"><strong>Helix</strong> <strong>Sleep</strong></a><strong> premium mattresses: </strong><a href="https://helixsleep.com/tim" rel="noopener noreferrer" target="_blank"><strong>HelixSleep.com/Tim</strong></a><strong> (20% off any purchase) </strong></li><li><a href="https://incogni.com/tim" rel="noopener noreferrer" target="_blank"><strong>Incogni, </strong></a><strong>which automatically removes your personal data from the web, helping shield you from fraud, scams, and identity theft: </strong><a href="https://incogni.com/tim" rel="noopener noreferrer" target="_blank"><strong>Incogni.com/Tim</strong></a><strong> (use code TIM at checkout and get 60% off an annual plan)</strong></li></ul><p>Timestamps:</p><ul><li>[00:00:00] Start.</li><li>[00:06:07] What Strand does.</li><li>[00:08:19] The Boston dinner.</li><li>[00:11:05] The image of a body riddled with cancer.</li><li>[00:15:05] What stuck for the muggles in the pitch deck.</li><li>[00:17:14] A good drug vs. a good product.</li><li>[00:19:40] Tricking cancer into snitching on itself.</li><li>[00:27:38] The abscopal effect.</li><li>[00:34:04] Potency, specificity, and delivery.</li><li>[00:35:46] First principles thinking.</li><li>[00:36:38] The precipice of a revolution.</li><li>[00:41:14] The thousand people in the room.</li><li>[00:48:38] Psychedelic medicine as a cautionary tale.</li><li>[00:51:17] What actually catches a policymaker’s attention.</li><li>[00:53:42] Breakthrough vs. incremental.</li><li>[00:54:55] What’s in it for the policymakers?</li><li>[00:58:08] The 80/20 wish list.</li><li>[01:01:31] Australia’s CTN system.</li><li>[01:03:51] Sheep, psychedelics, and red-tape arbitrage.</li><li>[01:05:22] China’s clinical-trial flywheel vs. slow-motion American loss.</li><li>[01:06:53] The bicoastal biotech ethos.</li><li>[01:08:10] Can the FDA actually pull this off?</li><li>[01:12:12] The <em>Sophie’s Choice</em> of pharma development.</li><li>[01:14:16] Lost arts of founder mode.</li><li>[01:15:23] Rockets for tumors, T-cells, and beyond.</li><li>[01:19:16] Viral in policy circles.</li><li>[01:23:09] The <em>Washington Post</em> headline and the PickFu split test.</li><li>[01:27:56] Solution-first storytelling.</li><li>[01:33:54] RNA medicine and platform therapeutics.</li><li>[01:39:17] Moderna’s 62 days.</li><li>[01:40:33] Uber Eats and the de-risked launch.</li><li>[01:44:17] CEO blockers.</li><li>[01:45:52] Where’s biotech’s SpaceX moment?</li><li>[01:46:53] Elon Musk betting black on the wheel.</li><li>[01:51:55] AWS and the post-conviction / pre-consensus window.</li><li>[01:58:47] COVID politicization.</li><li>[01:59:46] Insulin, growth hormone, and the original platform story.</li><li>[02:01:35] Biotech as pharma’s little brother.</li><li>[02:03:29] More recent role models, Apple edition.</li><li>[02:04:50] Art Levinson, Steve Jobs, and the biotech-tech crossover.</li><li>[02:06:25] The iPhone as a delivery platform.</li><li>[02:08:25] Spotify’s problem and the future of bespoke medicine.</li><li>[02:10:07] Baby KJ and the limits of liver-only solutions.</li><li>[02:11:19] Parting thoughts.</li></ul><p>*</p><p><strong>For show notes and past guests on </strong><a href="https://tim.blog/podcast" rel="noopener noreferrer" target="_blank"><strong><em>The Tim Ferriss Show</em></strong></a><strong>, please visit</strong> <a href="https://tim.blog/podcast/?utm_source=podcast&amp;utm_medium=podcast&amp;utm_campaign=podcast-description" rel="noopener noreferrer" target="_blank"><strong>tim.blog/podcast</strong></a><strong>.</strong></p><p><strong>For deals from sponsors of </strong><a href="https://tim.blog/podcast" rel="noopener noreferrer" target="_blank"><strong><em>The Tim Ferriss Show</em></strong></a><strong><em>, </em>please visit </strong><a href="https://tim.blog/podcast-sponsors" rel="noopener noreferrer" target="_blank"><strong>tim.blog/podcast-sponsors</strong></a></p><p><strong>Sign up for Tim’s email newsletter (<em>5-Bullet Friday</em>) at </strong><a href="https://go.tim.blog/5-bullet-friday-1/" rel="noopener noreferrer" target="_blank"><strong>tim.blog/friday</strong></a><strong>.</strong></p><p><strong>For transcripts of episodes, go to </strong><a href="https://tim.blog/transcripts" rel="noopener noreferrer" target="_blank"><strong>tim.blog/transcripts</strong></a><strong>.</strong></p><p><strong>Discover Tim’s books: </strong><a href="https://tim.blog/books" rel="noopener noreferrer" target="_blank"><strong>tim.blog/books</strong></a><strong>.</strong></p><p><strong>Follow Tim:</strong></p><p><strong>Twitter</strong>: <a href="https://twitter.com/tferriss" rel="noopener noreferrer" target="_blank">twitter.com/tferriss</a>&nbsp;</p><p><strong>Instagram</strong>: <a href="https://instagram.com/timferriss/" rel="noopener noreferrer" target="_blank">instagram.com/timferriss</a></p><p><strong>YouTube</strong>: <a href="https://www.youtube.com/timferriss" rel="noopener noreferrer" target="_blank">youtube.com/timferriss</a></p><p><strong>Facebook</strong>: <a href="https://www.facebook.com/TimFerriss/" rel="noopener noreferrer" target="_blank">facebook.com/timferriss</a>&nbsp;</p><p><strong>LinkedIn: </strong><a href="http://linkedin.com/in/timferriss" rel="noopener noreferrer" target="_blank">linkedin.com/in/timferriss</a></p><p>See Privacy Policy at <a href="https://art19.com/privacy" rel="noopener noreferrer" target="_blank">https://art19.com/privacy</a> and California Privacy Notice at <a href="https://art19.com/privacy#do-not-sell-my-info" rel="noopener noreferrer" target="_blank">https://art19.com/privacy#do-not-sell-my-info</a>.</p>

Key Insights

  • Strand demonstrates an abscopal response in multiple cancer patients where injecting RNA instructions into one tumor causes the immune system to kill distant, uninnjected metastases throughout the body, not just nearby lesions.
  • Becraft argues the biotech industry has conflated 'good drugs' (effective at treating individual patients) with 'good products' (economically deployable at scale), claiming in vivo cell therapies costing $750,000 and taking three months to manufacture are scientifically successful but commercially unviable.
  • The regulatory bottleneck in genetic medicine consists of three interrelated problems—potency, specificity, and delivery—not delivery alone, contrary to common biotech industry wisdom.
  • Current FDA IND applications cost $25 million and require 18 months to approve, incentivizing companies to run first-in-human trials in China and Australia instead, causing American patients to lose access to experimental medicines.
  • Becraft proposes replacing FDA permission-based oversight with Australia's CTN (Clinical Trial Notification) system, where companies notify regulators and hospital IRBs assess safety directly, distributing regulatory burden across certified institutions nationwide.
  • The Washington Post op-ed achieved traction not by alarming policymakers but by framing clinical trial delays as a fixable problem with a clear solution, leading to congressional testimony and inclusion in the President's legislative priorities within two months.
  • Split-testing headlines via PickFu revealed that opportunity-framed messaging ('this is bad but here's how we fix it') dramatically outperformed problem-only framing for driving policy engagement and click-through rates.
  • Genetic medicine has been restricted to liver treatment for 30 years because the liver naturally filters blood and traps IV-administered genetic medicines, making this the unintended 'default' target organ.
  • Becraft claims biotech has become structurally similar to real estate development rather than technology, with 90% of companies designed as point-A-to-point-B asset plays sold to Big Pharma rather than built as generational companies.
  • The biotech investment community openly shorts biotech companies during commercial drug launches ('short the launch') because most biotech firms lack operational experience executing commercial scale, reflecting decades of M&A-dependent incentive structures.
  • Platform therapeutics require multiple delivery platforms for different body regions (tumors, T-cells, kidneys, brain) rather than one universal platform, with each platform representing distinct technological and manufacturing challenges.
  • Moderna's 62-day COVID vaccine development built on 12 years of foundational mRNA platform work, meaning the apparent speed masked decades of prior infrastructure development that enabled rapid payload switching.
  • Becraft identifies post-conviction pre-consensus as the critical investment moment: when insiders know something will work but before market consensus exists, requiring narrative skill to pull capital into generational bets.
  • Regulatory processes accumulate barriers over time (nuclear energy in America as example) through agencies adding oversight without removing obsolete requirements, creating cottage industries that defend existing burdens rather than enabling innovation.
  • Hyper-personalized medicine is economically impossible today but will become viable as delivery infrastructure scales, just as Spotify couldn't exist until smartphones made on-demand music accessible everywhere, suggesting a temporal sequencing requirement for business models to match technology maturity.

Topics

Programmable genetic medicine and RNA therapeuticsAbscopal response and tumor immunotherapyFDA regulatory reform and clinical trial streamliningPlatform therapeutics vs. single-drug developmentUS biotech competitiveness versus ChinaCapital formation and patient capital for long-term innovationMessage framing and storytelling for policy influenceDelivery infrastructure as bottleneck in genetic medicineHyper-personalization as future of medicineFirst-principles thinking in biotechnologyBiotech's reliance on Big Pharma M&A incentives

Transcript

In genetic medicine, I would call it the holy grail for the last 30 years has been thinking about how do we administer intravenous, which means into the bloodstream, genetic medicines that can get to places throughout the body. We've been trapped in one organ for the past 30 years, and that's the liver. we are the first company that i'm aware of to show this extent of abscopal response in visceral deep organ metastases in a multitude of patients and really right off the bat what i want the world to understand is that we are standing right now on the precipice of a revolution in genetic medicine We're going to be able to get to a point in…

Full transcript available for MurmurCast members

Sign Up to Access

More from The Tim Ferriss Show

Get AI summaries like this delivered to your inbox daily

Get AI summaries delivered to your inbox

MurmurCast summarizes your YouTube channels, podcasts, and newsletters into one daily email digest.